Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
---|---|
Information provided by: | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
ClinicalTrials.gov Identifier: | NCT00000438 |
This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating alcoholism. Individuals will be inpatients for a 2 week period and provide assessments of their alcohol withdrawal symptoms, craving, and mood. Following hospital discharge, individuals will be assigned randomly to receive naltrexone daily, naltrexone twice a day or a placebo. This part of the study will last 12 weeks, with regular measurements of drinking level, craving and mood. Assessments will be conducted 6 and 12 months after the beginning of the study.
Condition | Intervention | Phase |
---|---|---|
Alcoholism |
Drug: naltrexone (Revia) |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Placebo Control, Efficacy Study |
Official Title: | Naltrexone Treatment for Alcoholism: Predicting Outcome |
Ages Eligible for Study: | 30 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | NIAAAMCC11855 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000438 |
Health Authority: | United States: Federal Government |
Mental Disorders Naltrexone Alcoholism |
Substance-Related Disorders Disorders of Environmental Origin Alcohol-Related Disorders |
Sensory System Agents Therapeutic Uses Physiological Effects of Drugs Narcotic Antagonists |
Peripheral Nervous System Agents Central Nervous System Agents Pharmacologic Actions |